2014/11/05 by Kamran Kaveh, Kaveh, Kamran, Venkata S. K. Manem +7
Biochemistry, Genetics and Molecular Biology · Mathematics · Medicine · #Biology #Cancer #DNA Repair Mechanisms #Effects of Radiation Exposure #Evolution and Genetic Dynamics #FOS: Biological sciences #Genetic Associations and Epidemiology #Genetics #Internal medicine #Mathematical Biology Tumor Growth #Medicine #Mutation #Mutation rate #Oncology #Population #Quantitative Methods (q-bio.QM) #Radiation therapy #Tissues and Organs (q-bio.TO) #q-bio.QM #q-bio.TO
paper · pdf · doi:10.48550/arxiv.1411.1448
24 pages, 16 figures, appears in Rad. Env. BioPhys 2014
arxiv created 2014/11/05 · openalex publication_date 2014/11/05 · arxiv updated 2014/11/07 · openalex created_date 2022/10/04 · openalex updated_date 2026/08/06
Although the survival rate of cancer patients has significantly increased due\nto advances in anti-cancer therapeutics, one of the major side effects of these\ntherapies, particularly radiotherapy, is the potential manifestation of\nradiation-induced secondary malignancies. In this work, a novel evolutionary\nstochastic model is introduced that couples short-term formalism (during\nradiotherapy) and long-term formalism (post treatment). This framework is used\nto estimate the risks of second cancer as a function of spontaneous background\nand radiation-induced mutation rates of normal and pre-malignant cells. By\nfitting the model to available clinical data for spontaneous background risk\ntogether with data of Hodgkins lymphoma survivors (for various organs), the\nsecond cancer mutation rate is estimated. The model predicts a significant\nincrease in mutation rate for some cancer types, which may be a sign of genomic\ninstability. Finally, it is shown that the model results are in agreement with\nthe measured results for excess relative risk (ERR) as a function of exposure\nage, and that the model predicts a negative correlation of ERR with increase in\nattained age. This novel approach can be used to analyze several radiotherapy\nprotocols in current clinical practice, and to forecast the second cancer risks\nover time for individual patients.\n